Cambridge Epigenetix fetches $88m Series D

Cambridge Epigenetix, a life sciences tools and technology company, has raised $88 million in Series D financing.

Cambridge Epigenetix, a life sciences tools and technology company, has raised $88 million in Series D financing. Temasek led the round with participation from other investors that included Third Point, GV, New Science Ventures, Ahren Innovation Capital and Sequoia.

Source: Press Release